Suspended

Docetaxel and Epirubicin as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Adenocarcinoma of the Stomach

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
What is being tested

docetaxel

+ epirubicin hydrochloride
Drug
Who is being recruted

Gastric Cancer

From 18 to 75 Years

See all eligibility criteria

How is the trial designed

Treatment Study

Phase 2
Interventional
Study Start: April 2001

See protocol details

Summary

Principal SponsorGERCOR - Multidisciplinary Oncology Cooperative Group
Last updated: July 24, 2008
Sourced from a government-validated database.Claim as a partner
Study start date: April 1, 2001Actual date on which the first participant was enrolled.

RATIONALE: Drugs used in chemotherapy, such as docetaxel and epirubicin, work in different ways to stop tumor cells from dividing so they stop growing or die. Giving more than one drug may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving docetaxel together with epirubicin as first-line therapy works in treating patients with locally advanced or metastatic adenocarcinoma (cancer) of the stomach. OBJECTIVES: Primary * Determine the objective tumor response rate and time to tumor progression in patients with locally advanced or metastatic adenocarcinoma of the stomach treated with docetaxel and epirubicin as first-line therapy. Secondary * Determine the survival without local relapse and overall survival of patients treated with this regimen. * Determine the tolerance to this regimen in these patients. OUTLINE: This is an open-label, multicenter study. Patients receive epirubicin IV over 30 minutes and docetaxel IV over 1 hour on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. PROJECTED ACCRUAL: A total of 39 patients will be accrued for this study.

Official TitlePhase II Study of Docetaxel and Epirubicine as First-Line Treatment in Patients With Advanced or Metastatic Adenocarcinoma of the Stomach 
Principal SponsorGERCOR - Multidisciplinary Oncology Cooperative Group
Last updated: July 24, 2008
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.
Design Details
Treatment Study
These studies test new ways to treat a disease, condition, or health issue. The goal is to see if a new drug, therapy, or approach works better or has fewer side effects than existing options.

How the interventions assigned to participants is kept confidential
Everyone involved in the study knows which treatment is being given. This is typically used when it's not possible or necessary to hide the treatment details from participants or researchers.

Other Ways to Mask Information
Single-blind: Participants do not know which treatment they are receiving, but researchers do.
Double-blind: Neither participants nor researchers know which treatment is given.
Triple-blind: Participants, researchers, and outcome assessors do not know which treatment is given.
Quadruple-blind: Participants, researchers, outcome assessors, and care providers all do not know which treatment is given.

Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Conditions
Criteria
Any sexBiological sex of participants that are eligible to enroll.
From 18 to 75 YearsRange of ages for which participants are eligible to join.
Healthy volunteers not allowedIf individuals who are healthy and do not have the condition being studied can participate.
Conditions
Pathology
Gastric Cancer
Criteria

DISEASE CHARACTERISTICS: * Histologically confirmed adenocarcinoma of the stomach * Locally advanced or metastatic disease * Measurable disease * At least 1 unidimensionally measurable target lesion at least 2 cm in diameter * No known symptomatic brain metastases * No bone metastases PATIENT CHARACTERISTICS: Age * 18 to 75 Performance status * ECOG 0-2 Life expectancy * At least 3 months Hematopoietic * Absolute neutrophil count at least 2,000/mm\^3 * Platelet count greater than 100,000/mm\^3 Hepatic * Bilirubin less than 2 times normal * AST and ALT no greater than 2.5 times normal * Alkaline phosphatase no greater than 2.5 times normal Renal * Creatinine less than 1.6 mg/dL OR * Creatinine clearance greater than 60 mL/min Cardiovascular * No serious cardiac failure within the past 12 months * No myocardial infarction within the past 12 months * No cardiac insufficiency * No angina Other * Not pregnant or nursing * Fertile patients must use effective contraception * No uncontrolled serious infection * No significant brain or psychiatric disorders * No intolerance to cortisone or polysorbate 80 * No other prior malignancy except curatively treated basal cell skin cancer or carcinoma in situ of the cervix * No other illness or medical condition that would preclude study participation * No peripheral neuropathy greater than grade 2 PRIOR CONCURRENT THERAPY: Biologic therapy * Not specified Chemotherapy * No prior chemotherapy Endocrine therapy * Not specified Radiotherapy * Not specified Surgery * Not specified Other * More than 21 days since prior participation in another clinical study * No other concurrent experimental medication

Study Plan

Find out more about all the medication administered in this study, their detailed description and what they involve.
Study Objectives
Study Objectives
Primary Objectives

Secondary Objectives

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.
This study has 23 locations
Suspended
Centre Paul PapinAngers, FranceSee the location
Suspended
Centre Hospitalier Victor DupouyArgenteuil, France
Suspended
Centre Hospital General Robert BallangerAulnay Sous Bois, France
Suspended
C.H.G. BeauvaisBeauvais, France
Suspended23 Study Centers